Clin Osteol 2011; 16(1): 16-19

Sclerostin - a new regulatory marker of bone turnover and a key target in the treatment of osteoporosisNews

V. Cirmanová, L. Stárka

Bone remodelling is a lifelong process of coordinated bone formation and resorption, which renews the skeleton while maintaining its structure. For this process, specialized cells are responsible: osteoblasts, osteoclasts and osteocytes. In recent years, considerable pro­ gress has been made in identifying molecular pathways involved in regulating bone metabolism. These discoveries facilitated the de­ velopment of new biochemical markers to monitor bone formation and resorption. Bone markers are useful for investigating the pa­ thophysiological processes of metabolic bone disorders and for developing new drugs for osteoporosis, rheumatoid arthritis and metastatic bone disease. For the regulation of bone remodelling, the Wnt signalling pathway is essential. A potent inhibitor of bone formation is a glycoprotein secreted by osteocytes - sclerostin. Monoclonal a of osteoporosis.

Keywords: bone remodelling, osteoporosis, osteosclerosis, sclerostin, AMG 785

Published: June 11, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cirmanová V, Stárka L. Sclerostin - a new regulatory marker of bone turnover and a key target in the treatment of osteoporosis. Osteologický bulletin. 2011;16(1):16-19.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Poole KE, Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secr duct of osteocytes that inhibits bone formation. FASEB J 2005;19:1842-1844. Go to original source...
    2. Kusu N, Laurikkala J, Imanishi M, et al. Sclerostin is a novel secreted osteoc derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003;278:24113-24117. Go to original source...
    3. Lewiecki EM. Sclerostin monoclonal antibody therapy with AMG 785: a poten­ tial treatment for osteoporosis. Expert Opinion on Biological Therapy 2011;11(1): 117-127. Go to original source...
    4. Moester MJ, Ppapoulos SE, Lowik CW, et al. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010 Aug;87(2):99-107. Go to original source...
    5. Hofbauer LC and Shoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 2004;292: 490-495. Go to original source...
    6. Kearns AE, Khosla S, Kostenuik PJ. Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease. Endocr Rev 2008;29:155-192. Go to original source...
    7. Luchavova M, Raska I. Novelties and possibility of prevention and treatment in outpatient clinic of general practicioner. Int med pro praxi 2011;13(2):74.
    8. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increa­ ses bone formation, bone mass, and bone strength in a rat model of postmenopau­ sal osteoporosis. J Bone Miner Res 2009;24:578-588. Go to original source...
    9. Bezooijen RL, Bronckers AL, Gortzak RA et al. Sclerostin in Mineralized Matrices and van Buchem Disease. J Dent Res 2009;88:569-574. Go to original source...
    10. Robling AG, Bellido T, Turner CH. Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact 2006;6:354.
    11. Bellido T, Ali AA, Gubrij I et. al. Chronic elevation ofparathyroid hormone ce reduces expression of sclerostin by osteocytes: a novel mechanism for hormo­ nal control of osteoclastogenesis. Endocrinology 2005;146(11):4577-4583. Go to original source...
    12. Mirza FS, Padhi ID, Raisz LG, et al. Serum sclerostin levels negatively c with parathyroid hormone levels and free estrogen index in postmenopausal wo­ men. J Clin Endocrinol Metab 2010;95(4):1991-1997. Go to original source...
    13. Gaudio A, Pennisi P, Bratengeier C, et al. Increased sclerostin serum levels ciated with bone formation and resorption markers in patients with immobiliza­ tion-induced bone loss. J Clin Endocrinol Metab 2010;95(5):2248-2253. Go to original source...
    14. Sutherland MK, Geoghegan JC, Yu C et al. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 2004;35:448-454. Go to original source...
    15. Wehmeyer C et al. Ann Rheum Dis 2010; 69 (Suppl2): A1-A76.
    16. Terpos E et al. Blood (ASH Meeting Abstracts) 2009; 114:425.
    17. Epstein S et al. Endocrine function in sclerosteosis. S Afr Med J 1979;55: 1105-1110.
    18. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin g ce results in increased bone formation and bone strength. J Bone Miner Res 2008;23:866-869. Go to original source...
    19. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin an nomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25:948-959. Go to original source...
    20. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized dy of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26(1):19-26. Go to original source...
    21. Marie PJ, Ammann P, Boivin G, et al. Mechanisms of action and therapeutic po­ tential of strontium in bone. Calcif Tissue Int 2001;69(3):121-129. Go to original source...
    22. Stein SA, Witkop C, Hill S, et al. Sclerosteosis: neurogenetic and pathophysi gic analysis of an American kinship. Neurology 1983;33:267-277. Go to original source...
    23. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human pa­ rathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88:5212-5220. Go to original source...
    24. Fox J, Miller MA, Newman MK, et al. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res 2007;22:260-273. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.